204 related articles for article (PubMed ID: 24449207)
1. Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
Wu LY; Johnson JM; Simmons JK; Mendes DE; Geruntho JJ; Liu T; Dirksen WP; Rosol TJ; Davis WC; Berkman CE
Prostate; 2014 May; 74(5):451-7. PubMed ID: 24449207
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Dowling M; Samuelson J; Fadl-Alla B; Pondenis HC; Byrum M; Barger AM; Fan TM
PLoS One; 2019; 14(1):e0210297. PubMed ID: 30601866
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of canine prostate-specific membrane antigen.
Schmidt S; Fracasso G; Colombatti M; Naim HY
Prostate; 2013 May; 73(6):642-50. PubMed ID: 23359458
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
Wu LY; Liu T; Grimm AL; Davis WC; Berkman CE
Prostate; 2011 Jan; 71(1):52-61. PubMed ID: 20632319
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Zhang Y; Guo Z; Du T; Chen J; Wang W; Xu K; Lin T; Huang H
Prostate; 2013 Jun; 73(8):835-41. PubMed ID: 23255296
[TBL] [Abstract][Full Text] [Related]
7. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Kazak M; Berkman CE
Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
[TBL] [Abstract][Full Text] [Related]
8. Verification of a canine PSMA (FolH1) antibody.
Wagner S; Maibaum D; Pich A; Nolte I; Murua Escobar H
Anticancer Res; 2015 Jan; 35(1):145-8. PubMed ID: 25550545
[TBL] [Abstract][Full Text] [Related]
9. PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
Simons BW; Turtle NF; Ulmert DH; Abou DS; Thorek DLJ
Prostate; 2019 May; 79(6):678-685. PubMed ID: 30656716
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.
Kwon YD; Oh JM; La MT; Chung HJ; Lee SJ; Chun S; Lee SH; Jeong BH; Kim HK
Bioconjug Chem; 2019 Jan; 30(1):90-100. PubMed ID: 30485073
[TBL] [Abstract][Full Text] [Related]
11. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
13. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
Yuan W; Liu B; Sanda M; Wei R; Benicky J; Novakova Z; Barinka C; Goldman R
Prostate; 2022 Jan; 82(1):132-144. PubMed ID: 34662441
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.
Mannweiler S; Amersdorfer P; Trajanoski S; Terrett JA; King D; Mehes G
Pathol Oncol Res; 2009 Jun; 15(2):167-72. PubMed ID: 18802790
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Kuroda K; Liu H
Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Chen W; Lee Z; Awadallah A; Zhou L; Xin W
Diagn Pathol; 2020 Jul; 15(1):92. PubMed ID: 32703222
[TBL] [Abstract][Full Text] [Related]
18. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
19. Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer.
Wang X; Chen Y; Xiong Y; Zhang L; Wang B; Liu Y; Cui M
J Med Chem; 2023 May; 66(10):6889-6904. PubMed ID: 37161996
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
